Type PE E G-HPN C-HPN Primigravida 53 13 23 5
Multigravida 70 5 43 3 Total 123 (54.9%) 18 (8.0%) 66 (29.5%) 8 (3.6%) Type PE + C-HPN Total p-value Primigravida 3 97 0.040
Multigravida 6 127 Total 9 (4.0%) 224 (100%) PE: preeclampsia; E: eclampsia; G-HPN: gestational hypertension; C- HPN: chronic hypertension; PE + C-HPN: preeclampsia superimposed on chronic hypertension.
Multigravida women had 3.5 times more likelihood of facing anemia than primigravida.
Almost all of the participants with HBsAg positivity were married and 70.6% were
multigravida. None of the sociodemographic and obstetrical characteristics of pregnant women assessed in this study was significantly associated with HBsAg positivity (Table 1).
The bivariate logistic regression showed that the primigravida mothers had 84% times lower odds of perinatal depression compared to the grand
multigravidas [OR (95% C.I): 0.16 (0.08, 0.31)].
47.8% and 47.0% of babies who did not survive were of primigravida and
multigravida mothers, respectively.
In group-A, 32.3% of patient were primigravida and 67.7% were
multigravida, similarly 33.3% were primigravida and 66.7%
multigravida in group B (Table 1).
Multigravida and multiparous women are more likely to develop GDM compared to primigravida and nulliparous women; however, after adjusting for age, prepregnancy BMI, and other confounders, the excess risk disappears.[sup][21] We did not find any association between gravidity and parity and higher rate of GDM.
Primigravida was 44% and
multigravida was 56% in the study group.
Demographic variables were; age, parity in terms of primi and
multigravida, antenatal care received or not and research variable was maternal outcome in terms of discharged alive or expired.
For the analysis purposes, the gravidity was divided into primigravida,
multigravida and grandmultigravida (more than 5 pregancies) and age of initiation of smokeless tobacco was divided into (i) less than 10 years, (ii) 11-29 years (iii) 30-40 years.
Multigravida: A woman who is pregnant for the second or subsequent time.
This information especially offers an advantage for
multigravida patients who have been previously sensitized with anti-D.
